| 2012 |
Primary endpoint of phase II GBM study with APG101 met |
| 2011 |
Completion of patient recruitment of phase II GBM study with APG101 |
| 2010 |
„Orphan Drug Designation“ for APG101 in EU and USA (Indication: GBM) |
| 2009 |
Start of phase II with APG101 (Indication: GBM) |
| 2008 |
Start of phase I with APG101; 2nd financing round: € 28 million |
| 2007 |
Establishment of GMP-production for APG101 |
| 2006 |
„Orphan Drug Designation“ for APG101 in EU (Indication: acute Graft-versus-Host Disease, aGvHD) |
| 2005 |
Foundation of Apogenix; 1st financing round: € 15 million |
